BioVie, Inc. (BIVI) Starts Presentation at LD Micro 2017 Invitational
BioVie (OTC: BIVI) is a development-stage biotech that discovers, develops and commercializes various drug therapies in the Unites States. The company focuses on the commercialization of BIV201 for the treatment of ascites due to liver cirrhosis. It also discovers and develops broad spectrum antibiotics for gram-negative and gram-positive bacterial infections. BioVie was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie was founded in 2013 and is based in Beverly, Massachusetts. For more information, visit the company's website at www.biovieinc.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1)…